3PBIOVIAN is a leading biopharmaceuticals contract development and manufacturing organization (CDMO), delivering end-to-end services to biotech and pharma companies, from early development to finished vial, for biological processes covering microbial and mammalian protein expression platforms, cell and gene therapy and plasmid DNA production. The company has a 40-year track record and serves its global customer base from its two manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland. Keensight Capital provided an equity investment alongside management to support the next phase of the company’s development.